SATURNA CAPITAL CORP has increased their stake in Abbvie (ABBV) by adding 40,521 shares to their portfolio. With several favorable trends appearing, AbbVie has become an attractive bet in the stock market. A long-term leap ratio spread strategy is being suggested for this pharmaceutical giant. A Biologics License Application for TrenibotulinumtoxinE has been submitted by AbbVie to the U.S. FDA. The first quarter financial results from 2025 were also reported by the company. Further, AbbVie's RINVOQ has received FDA approval for treating Giant Cell Arteritis. The company's price target has been raised to $216 by Guggenheim. Due to the success of two major drugs, the company has upgraded its outlook. It is also attracting billionaire attention like Ken Fisher's, who sees significant upside potential in the stock. The Q1 financial performance exceeded expectations led it moving up 8% for the week. Despite short-term market losses, confidence in the stock's long-term potential seems to be growing significantly.
Abbvie ABBV News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Fri, 02 May 2025 21:25:00 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -2
